Sight Sciences, Inc. (NASDAQ: SGHT) observed a notable surge in its stock value during the after-hour session on Tuesday, marking an increase of 18.20% to $6.43. This rise followed a preceding uptick of 2.45% during the regular trading session, culminating in a closing price of $5.44. The upward momentum of SGHT stock on the US stock charts coincided with the revelation of trial outcomes, which are planned to be disseminated through both oral and poster presentations at a significant industry event.
Sight Sciences (SGHT) disclosed findings from studies into two of its proprietary technologies. SGHT's TearCare System and the OMNI Surgical System are intended to treat glaucoma and dry eye disease ("DED"). Two oral presentations and two poster displays at the next ASCRS Annual Meeting, which takes place in Boston, Massachusetts from April 5–8, are planned to highlight these discoveries.
The OMNI technology is intended to improve the ability of surgeons to perform a thorough, minimally invasive, implant-free surgical surgery for individuals with primary open-angle glaucoma ("POAG"). Conversely, the TearCare technology facilitates a proprietary interventional procedure targeting diseased meibomian glands, offering localized heat therapy for adult patients grappling with evaporative DED stemming from meibomian gland dysfunction, when combined with manual expression of the meibomian glands.
At ASCRS, SGHT intends to present supplementary data reinforcing the efficacy and safety profiles of its OMNI and TearCare technologies. In addition to the existing robust corpus of clinical evidence, the company will present fresh data showcasing compelling OMNI outcomes over a 36-month period, underscoring the enduring efficacy of OMNI. Furthermore, new TearCare data will be unveiled, endorsing the utilization of TearCare technology as a primary therapeutic modality for DED.
These findings reaffirm the notion that TearCare stands as a preferred treatment option for DED linked to meibomian gland dysfunction. Phase 1 of the SAHARA trial demonstrated that the interventional TearCare procedure delivered statistically superior and sustained improvements in tear break-up time and various measures of meibomian gland secretion compared to treatment with Restasis. In phase 2 of the study, a single TearCare procedure surpassed the outcomes achieved with six months of Restasis in terms of alleviating signs and symptoms for patients.